In a patient with antisynthetase syndrome (Jo-1+, ILD, and myositis) treated with IVIG, mycophenolate, and tacrolimus, would you stop the IVIG after lung transplant? Myositis has not been active. What is the risk of recurrence of ILD after lung transplant?

Community
Company
News
Contact Us
Sign in

Topics: Rheumatology • Interstitial lung disease

Related Questions

How do you approach the treatment of indeterminate UIP on HRCT with grossly positive MPO antibody and no other features consistent with AAV?

Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?

Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?

Would nintedanib offer benefit to a patient with scleroderma (Anti-Th/To+/SSA+) who has CT chest with typical UIP pattern?

In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?

What is your approach to using nintedanib in patients on baseline immunosuppression?

How would you approach medication de-escalation in a patient with a history of rapidly progressive CTD-ILD who responded to and is currently on mycophenolate 3 grams daily and IVIG 2mg/kg monthly infusions and has been stable for two years?

What indicators do you use to determine whether a patient is having a favorable or unfavorable response to nintedanib?

How do you counsel and manage joint pain after isotretinoin treatment?

When prescribing hydroxychloroquine, how do you explain the mechanism of action and how this translates into clinical benefit for the patient?